Details of the Drug

General Information of Drug (ID: DMH5LFR)

Drug Name
ALXN6000
Synonyms Samalizumab
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 2 [1]
Chronic lymphocytic leukaemia 2A82.0 Phase 1/2 [2]
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
D0OY9L
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Membrane glycoprotein OX2 (CD200) TT0BE68 OX2G_HUMAN Not Available [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT00648739) Safety and Dose Ranging Study of ALXN6000 to Treat Relapsing or Refractory CLL or MM. U.S. National Institutes of Health.
3 American Society of Hematology, 52nd Annual Meeting and Exposition. P T. 2011 February; 36(2): 100-103.